1. Generics Bulletin

Teva Bows To $1.4bn US Ingrezza IP With Far Future Settlement

Israeli Firm Must Wait To Broaden TD Portfolio With Distant Settlement Deal

 
• By Dean Rudge

Teva has found a settlement deal with Neurocrine over the TD blockbuster Ingrezza.

TEVA
• Source: Shutterstock

Teva will be able to launch its US generic version of Neurocrine Biosciences’ Ingrezza (valbenazine) treatment for tardive dyskinesia in early 2040, after reaching a settlement agreement with the originator that resolves Hatch-Waxman litigation between the pair sparked by the Israeli firm’s valbenazine abbreviated new drug application.

The deal grants Teva the right to sell its generic versions of Ingrezza capsules in the US beginning on the 1 February 2040, or earlier under certain circumstances, subject to approval from both

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Generics Bulletin

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.